Seasonal Influenza
Conditions
Brief summary
This is an open-label, randomized and controlled phase Ⅳ clinical trial of quadrivalent influenza vaccine manufactured by Sinovac Biotech Co. , the purpose of this study is to compare the immunogenicity and safety after 1 dose of quadrivalent influenza vaccine with that of 2 doses in vaccine-unprimed children aged 3-8 years old,to compare the immunogenicity and safety after 1 dose of quadrivalent influenza vaccine in vaccine-unprimed children aged 3-8 years old with that of 1 dose in vaccine-primed children and to compare the immunogenicity and safety after 2 doses of quadrivalent influenza vaccine in vaccine-unprimed children aged 3-8 years old with that of 1 dose in vaccine-primed children.
Detailed description
This study is open-label, randomized and controlled phase Ⅳ clinical trial of quadrivalent influenza vaccine.The purpose of this study is to compare the immunogenicity and safety after 1 dose of quadrivalent influenza vaccine with that of 2 doses in vaccine-unprimed children aged 3-8 years old,to compare the immunogenicity and safety after 1 dose of quadrivalent influenza vaccine in vaccine-unprimed children aged 3-8 years old with that of 1 dose in vaccine-primed children and to compare the immunogenicity and safety after 2 doses of quadrivalent influenza vaccine in vaccine-unprimed children aged 3-8 years old with that of 1 dose in vaccine-primed children.A total of 600 subjects including 400 vaccine-unprimed children and 200 vaccine-primed children will be enrolled,400 vaccine-unprimed children will be randomly divided into two groups in a 1:1 ratio.Subjects in group 1(experimental group 1 ) will receive two doses of quadrivalent influenza vaccine on the immunization schedule of day 0,28 and subjects in group 2 (experimental group 2) will receive one dose of quadrivalent influenza vaccine.200 vaccine-primed children (experimental group 3) will receive one dose of quadrivalent influenza vaccine.
Interventions
BIOLOGICALTwo doses of quadrivalent influenza vaccine
15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
BIOLOGICALOne dose of quadrivalent influenza vaccine
15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
Sponsors
Sinovac Biotech Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 8 Years
Healthy volunteers
Yes
Inclusion criteria
vaccine-unprimed children Inclusion Criteria: * Healthy children aged 3-8 years; * The subjects' guardians can understand and voluntarily sign the informed consent form; * Proven legal identity.
Exclusion criteria
* Received any circulating seasonal influenza vaccine prior to enrollment or had an influenza vaccine schedule during the study; * Suffering from seasonal influenza in the past 6 moths; * History of asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema; * Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; * Autoimmune disease or immunodeficiency / immunosuppression; * Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc.; * Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; * Thyroid disease or history of thyroidectomy, asplenia,functional asplenia, asplenia or splenectomy resulting from any condition; * Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation; * Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months; * History of drug abuse; * Receipt of blood products within in the past 3 months; * Receipt of other investigational drugs in the past 30 days; * Receipt of inactivated or subunit vaccines in the past 7 days; * Acute diseases or acute exacerbation of chronic diseases in the past 7 days; * Axillary temperature \>37.0°C; * According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial. vaccine-primed children Inclusion Criteria: * Healthy children aged 3-8 years; * The subjects' guardians can understand and voluntarily sign the informed consent form; * Proven legal identity; * Received at least 1 dose of seasonal influenza vaccine in previous epidemic seasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity index of the seroconversion rate | 28 days after the vaccination of the last dose | The seroconversion rate of each influenza strain after each dose of quadrivalent influenza vaccine |
| Immunogenicity index of the seroprotective rate | 28 days after the vaccination of the last dose | The seroprotective rate of each influenza strain after each dose of quadrivalent influenza vaccine |
| Immunogenicity index of the GMT | 28 days after the vaccination of the last dose | The GMT of each influenza strain after each dose of quadrivalent influenza vaccine |
| Immunogenicity index of the GMI | 28 days after the vaccination of the last dose | The GMI of each influenza strain after each dose of quadrivalent influenza vaccine |
| Safety index of the incidence of adverse reactions | From day 0 to day 7 after each dose vaccination | The incidence of adverse reactions within 0-7 days after each dose |
| Safety index of the incidence of serious adverse events(SAEs) | From the beginning of the vaccination to 28 days after the whole-schedule vaccination | The incidence of serious adverse events from the beginning of vaccination to 28 days after the last dose |
Countries
China
Outcome results
None listed